Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low-Dose Ha44 0.37% w/w · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes. |
| Group B | EXPERIMENTAL | Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration. |
| Group C | PLACEBO_COMPARATOR | Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration. |
| Name | Type | Description |
|---|---|---|
| Group A - Low-Dose Ha44 0.37% w/w | DRUG | Low Dose Ha44 Gel applied to scalp and hair for 10 minutes |
| Group B - High Dose Ha44 Gel 0.74% w/w | DRUG | High Dose Ha44 Gel applied to scalp and hair for 10 minutes |
| Group C - Placebo | DRUG | Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes |
Inclusion Criteria: * 2 years of age or older * Body weight of at least 33 pounds * Has an active head lice infestation at Day 0. An active infection is defined as at least 3 live lice for the index subject and at least 1 live louse for the other household members * Belong to a household of no more...
Low-Dose Ha44 0.37% w/w is being developed for the treatment of pediculosis, commonly known as head lice infestation. It is a topical gel applied to the scalp. The candidate is a small molecule in the dermatology therapeutic area and is designed for topical administration in patients with head lice.
Low-Dose Ha44 0.37% w/w is being developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. The company sponsored the clinical program evaluating the topical gel for head lice infestation. No partnership or licensing arrangement for this asset is disclosed in the available program information.
Low-Dose Ha44 0.37% w/w is in Phase 2 development. It is an investigational topical gel and has not been approved for marketing. The Phase 2 program has been completed, and no active trials for this candidate are currently listed.
Low-Dose Ha44 0.37% w/w has been studied in one completed Phase 2 trial, NCT01336647, titled an efficacy and safety study of Ha44 gel administered topically for the treatment of head lice infestation. The trial enrolled 142 participants in the United States, included patients aged 2 years and older, and was randomized, double blind, and placebo controlled.